Will Covid drug Evusheld be offered to vulnerable Britons who don't respond to vaccine? - Daily Mail

Evusheld, developed by AstraZeneca, was approved by drug regulators in March after a study showed it reduced the chances of Covid infections by 80 per cent.

Health chiefs are poised to roll out a life-saving Covid drug designed to protect vulnerable patients who don't respond to the vaccine, The Mail on Sunday has learned. Government experts have been a… [+4369 chars]

full article...